Nexus Finance
LONN.SW LONZA N | CH0013841017

Company Profile

Lonza Group AG, together with its subsidiaries, operates as a contract development and manufacturing organization for pharma and biotech companies in Europe, North and Central America, Latin America, Asia, Australia, New Zealand, and internationally. It operates through Integrated Biologics; Advanced Synthesis; and Specialized Modalities segments. The Integrated Biologics segment offers CDMO biologics services from clinical development, drug substance, and drug product manufacturing; and operates mammalian and drug product platforms. Its Advanced Synthesis segment manufactures antibody-drug conjugates (ADCs) and other bioconjugates, small molecules, and highly potent active pharmaceutical ingredients; and operates small molecules and bioconjugates platforms. The Specialized Modalities segment operates various technologies, such as spanning cell & gene, microbial, bioscience, and mRNA. Lonza Group AG was incorporated in 1897 and is headquartered in Basel, Switzerland.

Latest News

Sector Healthcare
Industry Diagnostics & Research
Website https://www.lonza.com
Audit Risk 3
Board Risk 1
Overall Risk 1
Market Cap 38.27B
Trailing P/E 35.33
Forward P/E 25.03
Dividend Rate 5
Dividend Yield 0.91%
Trailing Annual Div. Rate 5
Trailing Annual Div. Yield 0.92%
Trailing EPS 15.51
Forward EPS 21.9
Book Value 116.37
Price-to-Book 4.71
Enterprise-to-Revenue 6.11
Enterprise-to-EBITDA 17.55
Ex-Dividend Date 05/12/2026
Dividend Date 05/15/2025
Earnings Date
Earnings Call Date 07/22/2026
ende